tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Allogene Therapeutics Inc

ALLO
Add to Watchlist
1.040USD
-0.050-4.59%
Close 11-06 16:00（ET）
359.31MMarket Cap
LossP/E TTM
Pre-market 08:01 (ET)1.070USD+0.030+2.88%

Allogene Therapeutics Inc

1.040
-0.050-4.59%
Overview
News&Analysis
Financials
Stock Score
Technical
Forecast
Ownership
Dividends
Profile
Discussions
Financial SummaryIncome StatementBalance SheetCash Flow StatementEarningsCompany ValuationRisk Assessment

Overview

News&Analysis

Financials

Stock Score

Technical

Forecast

Ownership

Dividends

Profile

Discussions

Financial SummaryIncome StatementBalance SheetCash Flow StatementEarningsCompany ValuationRisk Assessment

ALLO Financials

See Allogene Therapeutics Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.
Key Financial Ratios
Market Cap
359.31M
Dividend TTM
0.00
P/E TTM
-1.35
EPS TTM
-0.77
Revenue
0.00
Net Profit
-257.59M
ROE
-52.32%
ROA
-38.45%
Allogene Therapeutics Inc Earnings Date
Latest Release
Nov 5, 2026
EPS / Forecast
-0.15/-0.15
Revenue / Forecast
0.00/2.22K

Financial Statement Highlights

Quarterly
Quarterly+Annual
Quarterly
Annual
FY2026Q3
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
Financial Indicators
EPS
21.94%-0.15
44.24%-0.13
36.07%-0.18
39.66%-0.17
41.17%-0.19
33.36%-0.23
27.83%-0.28
44.17%-0.28
14.70%-0.32
35.30%-0.35
44.42%-0.38
22.55%-0.51
---0.37
---0.54
---0.69
---0.66
---1.67
----
----
----
Revenue
--0.00
--4.64M
----
--0.00
--0.00
--0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-26.67%22.00K
-55.32%21.00K
-55.10%22.00K
-74.42%22.00K
-50.82%30.00K
-99.94%47.00K
0.00%49.00K
95.45%86.00K
-99.84%61.00K
--75.65M
Net Profit
-21.66%-50.37M
16.23%-42.68M
28.67%-42.61M
35.25%-38.81M
37.55%-41.40M
23.23%-50.94M
8.10%-59.73M
30.12%-59.94M
-6.43%-66.29M
16.25%-66.36M
34.98%-65.00M
9.56%-85.78M
25.09%-62.29M
-5.94%-79.23M
-25.19%-99.97M
-110387.21%-94.85M
-6.35%-83.15M
-5.43%-74.79M
-141.86%-79.85M
100.13%86.00K
Net Margin
----
---919.76%
----
----
----
----
----
----
----
----
11.34%-295454.55%
-102.41%-408466.67%
---283122.73%
---360145.45%
---333226.67%
---201802.13%
---121318.88%
----
----
----
Gross Margin
----
--100.00%
----
----
----
----
----
----
----
----
0.00%100.00%
----
--100.00%
--100.00%
--100.00%
--100.00%
--100.00%
----
----
----
Income Statement
Revenue
--0.00
--4.64M
----
--0.00
--0.00
--0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-26.67%22.00K
-55.32%21.00K
-55.10%22.00K
-74.42%22.00K
-50.82%30.00K
-99.94%47.00K
0.00%49.00K
95.45%86.00K
-99.84%61.00K
--75.65M
Operating profit
-22.03%-54.79M
13.81%-46.92M
29.30%-46.09M
29.90%-42.40M
26.45%-44.90M
18.07%-54.44M
6.21%-65.19M
15.83%-60.49M
3.10%-61.05M
17.50%-66.44M
29.86%-69.50M
25.43%-71.86M
23.63%-63.00M
-5.15%-80.54M
-23.88%-99.09M
-5745.81%-96.37M
-6.20%-82.49M
-7.83%-76.59M
-140.93%-79.99M
102.46%1.71M
Net Profit
-21.66%-50.37M
16.23%-42.68M
28.67%-42.61M
35.25%-38.81M
37.55%-41.40M
23.23%-50.94M
8.10%-59.73M
30.12%-59.94M
-6.43%-66.29M
16.25%-66.36M
34.98%-65.00M
9.56%-85.78M
25.09%-62.29M
-5.94%-79.23M
-25.19%-99.97M
-110387.21%-94.85M
-6.35%-83.15M
-5.43%-74.79M
-141.86%-79.85M
100.13%86.00K
Balance Sheet
Current assets
15.00%299.83M
20.29%340.00M
-6.27%273.29M
-15.04%257.75M
-14.35%260.72M
-38.17%282.65M
-26.25%291.58M
-33.92%303.39M
-35.70%304.42M
-8.96%457.12M
-17.88%395.36M
-13.18%459.12M
-16.80%473.45M
-2.13%502.10M
2.50%481.46M
12.20%528.82M
13.17%569.06M
-14.80%513.03M
-34.40%469.74M
-44.23%471.32M
Total current liabilities
20.94%38.50M
0.16%31.73M
-5.64%28.33M
-8.47%32.51M
-2.27%31.83M
-15.09%31.68M
-2.82%30.02M
-4.20%35.52M
-13.46%32.57M
-31.83%37.30M
-48.15%30.89M
-30.99%37.08M
-22.99%37.64M
21.85%54.72M
61.58%59.59M
11.53%53.73M
-8.63%48.87M
-2.37%44.91M
-32.77%36.88M
-48.92%48.17M
Total assets
16.27%511.32M
16.89%550.09M
-22.05%395.96M
-24.20%415.90M
-25.35%439.77M
-27.25%470.59M
-13.37%507.98M
-14.64%548.71M
-17.30%589.12M
-16.10%646.88M
-21.49%586.35M
-21.76%642.84M
-19.74%712.33M
-18.64%770.97M
-22.57%746.87M
-20.90%821.58M
-17.76%887.57M
-15.89%947.64M
-18.19%964.63M
-15.41%1.04B
Total liabilities
-4.56%118.77M
-9.61%113.92M
-4.49%117.08M
-2.50%123.36M
-0.74%124.44M
-4.41%126.03M
-1.92%122.59M
-3.12%126.53M
-2.98%125.37M
-10.95%131.84M
-19.16%124.98M
-15.57%130.60M
-12.46%129.22M
1.63%148.06M
41.32%154.61M
26.56%154.70M
35.05%147.61M
41.57%145.69M
0.13%109.40M
-17.53%122.23M
Total equity
24.49%392.55M
26.59%436.18M
-27.64%278.88M
-30.71%292.54M
-32.00%315.33M
-33.10%344.56M
-16.47%385.39M
-17.58%422.18M
-20.47%463.75M
-17.32%515.04M
-22.10%461.37M
-23.19%512.23M
-21.20%583.10M
-22.33%622.91M
-30.75%592.26M
-27.23%666.88M
-23.71%739.96M
-21.67%801.95M
-20.06%855.23M
-15.12%916.41M
Cash Flow Statement
Net operating income
-21.66%-36.12M
18.02%-32.00M
75.60%-12.91M
24.79%-27.60M
32.70%-29.69M
38.62%-39.03M
5.31%-52.93M
31.67%-36.70M
20.56%-44.12M
-2.80%-63.59M
16.12%-55.90M
13.51%-53.71M
-16.53%-55.53M
-45.44%-61.86M
2.34%-66.64M
-36.67%-62.10M
2.50%-47.66M
-3.31%-42.53M
-38.33%-68.24M
-355.50%-45.44M
Net investment
118.82%26.12M
-436.62%-147.56M
-579.08%-29.59M
-38.81%33.61M
115.71%11.94M
-41.25%43.84M
-72.10%6.18M
-18.57%54.93M
-121.76%-75.99M
334.81%74.61M
-80.40%22.13M
36.02%67.46M
-237.59%-34.27M
-68.24%17.16M
604.69%112.94M
69.56%49.60M
91.39%24.91M
119.70%54.03M
-123.12%-22.38M
31.70%29.25M
Net financing
-80.04%646.00K
3604.10%187.87M
50.98%21.12M
36.84%7.86M
376.58%3.24M
-95.33%5.07M
747.88%13.99M
3605.16%5.74M
-84.15%679.00K
21.31%108.60M
-4.68%1.65M
236.96%155.00K
301.97%4.29M
372916.67%89.52M
-4.58%1.73M
-85.71%46.00K
-55.27%1.07M
-99.25%24.00K
-69.99%1.81M
-97.52%322.00K

FAQs

What are the current assets of Allogene Therapeutics Inc?

According to Allogene Therapeutics Inc's FY2025 earnings report, its current assets were 257.75M, with a year-on-year change of -15.04.

What are the total assets of Allogene Therapeutics Inc?

According to Allogene Therapeutics Inc's FY2025 earnings report, its total assets of Allogene Therapeutics Inc were 415.90M, with a year-on-year change of -24.20.

What are the total liabilities of Allogene Therapeutics Inc?

According to Allogene Therapeutics Inc's FY2025 earnings report, its total liabilities of Allogene Therapeutics Inc were 123.36M, with a year-on-year change of -2.50.

What is the total equity of Allogene Therapeutics Inc?

According to Allogene Therapeutics Inc's FY2025 earnings report, its total equity of Allogene Therapeutics Inc was 292.54M, with a year-on-year change of -30.71.

What is the net operating income of Allogene Therapeutics Inc?

According to Allogene Therapeutics Inc's FY2025 earnings report, its net operating income of Allogene Therapeutics Inc was -206.93M, with a year-on-year change of 19.63.

What is the net investment of Allogene Therapeutics Inc?

According to Allogene Therapeutics Inc's FY2025 earnings report, its net investment of Allogene Therapeutics Inc was 95.56M, with a year-on-year change of 26.25.

What is the net financing of Allogene Therapeutics Inc?

According to Allogene Therapeutics Inc's FY2025 earnings report, its net financing of Allogene Therapeutics Inc was 30.16M, with a year-on-year change of -74.15.

What is the Earnings Per Share (EPS) of Allogene Therapeutics Inc?

According to Allogene Therapeutics Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -0.87, with a year-on-year change of 34.57.

What is the net income of Allogene Therapeutics Inc?

According to Allogene Therapeutics Inc's FY2025 earnings report, its net income was -190.89M, with a year-on-year change of 25.90.

What is the Return on Equity (ROE) of Allogene Therapeutics Inc?

According to Allogene Therapeutics Inc's FY2025 earnings report, its Return on Equity (ROE) was -53.42, with a year-on-year change of 3.12.

What is the Return on Assets (ROA) of Allogene Therapeutics Inc?

According to Allogene Therapeutics Inc's FY2025 earnings report, its Return on Assets (ROA) was -39.58, with a year-on-year change of 8.46.

What is the operating profit of Allogene Therapeutics Inc?

According to Allogene Therapeutics Inc's FY2025 earnings report, its operating profit was -206.93M, with a year-on-year change of 19.63.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy